1
|
Sassano A and Platanias LC: Statins in
tumor suppression. Cancer Lett. 260:11–19. 2008.
|
2
|
Hindler K, Cleeland CS, Rivera E and
Collard CD: The role of statins in cancer therapy. Oncologist.
11:306–315. 2006.
|
3
|
Sivaprasad U, Abbas T and Dutta A:
Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase
inhibitors on the cell cycle of prostate cancer cells. Mol Cancer
Ther. 5:2310–2316. 2006.
|
4
|
Campbell MJ, Esserman LJ, Zhou Y, et al:
Breast cancer growth prevention by statins. Cancer Res.
66:8707–8714. 2006.
|
5
|
Martirosyan A, Clendening JW, Goard CA and
Penn LZ: Lovastatin induces apoptosis of ovarian cancer cells and
synergizes with doxorubicin: potential therapeutic relevance. BMC
Cancer. 10:1032010.
|
6
|
Sassano A, Katsoulidis E, Antico G, et al:
Suppressive effects of statins on acute promyelocytic leukemia
cells. Cancer Res. 67:4524–4532. 2007.
|
7
|
Escárcega RO, Fuentes-Alexandro S,
García-Carrasco M, Gatica A and Zamora A: The transcription factor
nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol).
19:154–161. 2007.
|
8
|
Bharti AC and Aggarwal BB: Nuclear
factor-kappa B and cancer: its role in prevention and therapy.
Biochem Pharmacol. 64:883–888. 2002.
|
9
|
Ahn KS, Sethi G and Aggarwal BB: Reversal
of chemoresistance and enhancement of apoptosis by statins through
down-regulation of the NF-kappaB pathway. Biochem Pharmacol.
75:907–913. 2008.
|
10
|
Dai Y, Khanna P, Chen S, Pei XY, Dent P
and Grant S: Statins synergistically potentiate
7-hydroxystaurosporine (UCN-01) lethality in human leukemia and
myeloma cells by disrupting Ras farnesylation and activation.
Blood. 109:4415–4423. 2007.
|
11
|
Tomiyama N, Matzno S, Kitada C, Nishiguchi
E, Okamura N and Matsuyama K: The possibility of simvastatin as a
chemotherapeutic agent for all-trans retinoic acid-resistant
promyelocytic leukemia. Biol Pharm Bull. 31:369–374. 2008.
|
12
|
van der Weide K, de Jonge-Peeters SD,
Kuipers F, de Vries EG and Vellenga E: Combining simvastatin with
the farnesyltransferase inhibitor tipifarnib results in an enhanced
cytotoxic effect in a subset of primary CD34+ acute
myeloid leukemia samples. Clin Cancer Res. 15:3076–3083. 2009.
|
13
|
Toubi E and Shoenfeld Y: Toll-like
receptors and their role in the development of autoimmune diseases.
Autoimmunity. 37:183–188. 2004.
|
14
|
Bassères DS and Baldwin AS: Nuclear
factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic
initiation and progression. Oncogene. 25:6817–6830. 2006.
|
15
|
Courtois G and Gilmore TD: Mutations in
the NF-kappaB signaling pathway: implications for human disease.
Oncogene. 25:6831–6843. 2006.
|
16
|
Pasare C and Medzhitov R: Toll-like
receptors: linking innate and adaptive immunity. Adv Exp Med Biol.
560:11–18. 2005.
|
17
|
Suzuki N, Suzuki S, Duncan GS, et al:
Severe impairment of interleukin-1 and Toll-like receptor
signalling in mice lacking IRAK-4. Nature. 416:750–756. 2002.
|
18
|
Ninomiya-Tsuji J, Kishimoto K, Hiyama A,
Inoue J, Cao Z and Matsumoto K: The kinase TAK1 can activate the
NIK-I kappaB as well as the MAP kinase cascade in the IL-1
signalling pathway. Nature. 398:252–256. 1999.
|